DPMAS联合PE治疗肝衰竭的临床效果观察

摘要/Abstract

摘要： 目的研究双重血浆分子吸附系统(DPMAS)联合血浆置换(PE)治疗肝衰竭的效果。方法纳入广东省人民医院2018年10月至2022年5月收治的138例肝衰竭患者,根据随机、对照、双盲原则,以随机数字表法将患者分为A、B、C 3组,每组46例。A组行DPMAS治疗,B组行PE治疗,C组行DPMAS序贯PE治疗。记录3组治疗效果。检测3组患者肝功能指标(AST、ALT、TBil)、血清细胞因子(TNF-α、IFN-γ及IL-6)及凝血功能指标(PT、INR、PTA)水平变化情况。结果治疗第90天时C组显效22例,有效14例,无效3例,死亡7例;显著优于A组(显效12例,有效19例,无效3例,死亡12例)和B组(显效11例,有效18例,无效3例,死亡14例)(Z=-2.044、-2.408,P=0.041、0.016)。B组治疗第28天、第90天时TBil为(201.1±77.4)μmol/L和(93.6±28.2)μmol/L,显著高于A组的(157.9±56.2)μmol/L和(80.2±21.7)μmol/L和C组的(162.7±50.2)μmol/L和(78.6±24.6)μmol/L(F=6.630、5.004,P=0.002、0.008)。C组治疗第90天时血清TNF-α、IFN-γ及IL-6分别为(20.6±14.4)pg/mL、(32.4±13.8)pg/mL及(31.7±10.1)ng/L,显著低于A组的(34.2±16.2)pg/mL、(43.2±18.4)pg/mL及(48.7±14.4)ng/L和B组的(35.7±17.3)pg/mL、(40.6±17.6)pg/mL及(50.0±12.8)ng/L(F=12.417、5.228、30.406,P<0.01、0.007、<0.01)。治疗第90天时A组PT和INR分别为(18.3±3.8)s和(1.23±0.11),显著高于B组的(15.1±3.6)s和(1.10±0.09)、C组的(14.6±3.9)s和(1.07±0.27),(F=13.052、10.722,均P<0.01)。结论 DPMAS序贯PE治疗方案用于肝衰竭患者,能发挥DPMAS和PE各自优势,清除细胞因子,改善凝血紊乱状态,保护肝功能,提高疗效。

关键词: 肝衰竭, 双重血浆分子吸附系统, 血浆置换, 细胞因子, 肝功能

Abstract: Objective To study the curative effect of double plasma molecular adsorption system (DPMAS) combined with plasma exchange (PE) on patients with liver failure. Methods A total of 138 patients with liver failure from October 2018 to May 2022 were enrolled. The patients were randomly divided into DPMAS group(Group A), PE group(Group B) and DPMAS+ PEgroup(Group C) with 46 cases in each group. The changes of liver function indexes (AST, ALT, TBil), the serum cytokines (TNF-α, IFN-γ and IL-6) and coagulation function (PT, INR, PTA) in the 3 groups were collected. Results On the 90th day of treatment, managment in Group C was assessed as markedly effective in 22 cases, effective in 14 cases and ineffective in 3 cases. 7 cases died during the treatment. The intervention outcomes for Group C outperformed those of both Group A(which had 12 effective cases, 19 effective cases, 3 ineffective cases and 12 deaths) and Group B(which had 11 effective cases, 18 effective cases, 3 ineffective cases, 14 deaths) (Z=-2.044, -2.408; P=0.041, 0.016). On the 28th and 90th of treatment, the levels of TBil in Group B[(201.1±77.4) μmol/L and (93.6±28.2) μmol/L, respectively] were significantly higher than those in Group A [(157.9±56.2) μmol/L and (80.2±21.7) μmol/L] and Group C [(162.7±50.2) μmol/L and (78.6±24.6) μmol/L, F=6.630、5.004,P=0.002、0.008]. On the 90th day of treatment, the serum levels of TNF-α, IFN-γ and IL-6 in Group C[(20.6±14.4) pg/mL, (32.4±13.8) pg/mL and (31.7±10.1) ng/L, respectively] were significantly lower than those in group A [(34.2±16.2) pg/mL, (43.2±18.4) pg/mL and (48.7±14.4) ng/L] and group B [(35.7±17.3) pg/mL, (40.6±17.6) pg/mL and (50.0±12.8) ng/L]. F=12.417、5.228、30.406,all P<0.05]. On the 90th day of treatment, PT and INR in Group A[(18.3±3.8) s and (1.23±0.11), respectively] were significantly higher than those in Group B [(15.1±3.6) s and (1.10±0.09)] and Group C [(14.6±3.9) s and (1.07±0.27), F=13.052、10.722,P=0.000、0.000]. Conclusion The DPMAS sequential PE therapy for patients with liver failure effectively leverages the strengths of both DPMAS and PE. It is capable of clearing cytokines, improving coagulation disorder, safeguarding liver function and thereby enhancning the overal therapeutic efficacy.

Key words: Hepatic failure, Double plasma molecular adsorption system, Plasma exchange, Cytokines, Liver function

杨航, 罗永燕, 潘璐达, 张略韬, 宋素娜. DPMAS联合PE治疗肝衰竭的临床效果观察[J]. 肝脏, 2023, 28(6): 707-710.

YANG Hang, LUO Yong-yan, PAN Lu-da, ZHANG Lue-tao, SONG Su-na. Clinical efficacy of DPMAS combined with PE in the treatment of liver failure[J]. Chinese Hepatolgy, 2023, 28(6): 707-710.

参考文献

[1] Chen HS, Joo DJ, Shaheen M, et al. Randomized trial of spheroid reservoir bioartificial liver in porcine model of post‐hepatectomy liver failure. Hepatology, 2019,69(1):329-342.
[2] Yao J,Li S,Zhou L,et al.Therapeutic effect of double plasma molecular adsorption system and sequential half‐dose plasma exchange in patients with HBV‐related acute‐on‐chronic liver failure. J Clin Apher, 2019,34(4):392-398.
[3] 中华医学会感染病学分会肝衰竭与人工肝学组. 非生物型人工肝治疗肝衰竭指南(2016年版). 中华临床感染病杂志,2016,9(2):97-103.
[4] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 临床肝胆病杂志,2019,35(1):38-44.
[5] Flamm SL, Yang YX, Singh S, et al. American gastroenterological association institute guidelines for the diagnosis and management of acute liver failure.Gastroenterology, 2017, 152(3):644-647.
[6] Yonekawa C, Nakae H, Tajimi K, et al. Effectiveness of combining plasma exchange and continuous hemodiafiltration in patients with postoperative liver failure. Artif Organs, 2015, 29(4):324-328.
[7] Zhongyang X, Laurencia V, Ermei C, et al. A prognostic model for hepatitis B acute-on-chronic liver failure patients treated using a plasma exchange-centered liver support system. J Clin Apher, 2020, 35(2):94-103.
[8] Ma Y, Chen F, Xu Y, et al. Safety and efficacy of regional citrate anticoagulation during plasma adsorption plus plasma exchange therapy for patients with acute-on-chronic liver failure: A pilot study. Blood Purif, 2019, 48(3):223-232.
[9] Hanish SI, Stein DM, Scalea JR, et al. Molecular adsorbent recirculating system effectively replaces hepatic function in severe acute liver failure. Ann Surg, 2017,266(4):677-684.
[10] 钟韵,赵树山,黄燕,等. 单纯血浆置换与双血浆分子吸附系统联合半剂量血浆置换治疗重型肝炎患者疗效的Meta分析. 中国感染控制杂志,2020,19(5):417-425.
[11] 张秀灵,段志文,杨瑞东,等. 血源紧张条件下血浆置换联合双重血浆分子吸附系统治疗早中期肝衰竭患者临床研究. 实用肝脏病杂志,2019,22(2):289-290.
[12] Wang YJ, He NH, Wang ZW,et al. Assessment of the combined effect of plasma exchange and plasma perfusion on patients with severe hepatitis awaiting orthotopic liver transplantation. Int J Artif Organs, 2018, 27(1):40-44.
[13] Falkenhagen D, Strobl W, Vogt G, et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances.Artif Organs, 2015, 23(1):81-86.
[14] Prakash S, Hans R, Sharma R, et al. Therapeutic plasma exchange in a patient of myasthenic crisis, refractory to intravenous immunoglobulin and immunosuppressive therapy.Neurol India, 2017, 65(6):1409-1412.
[15] Jing L, Qian C, Jing Y, et al. IFN-γ contributes to the hepatic inflammation in HFD-induced nonalcoholic steatohepatitis by STAT1β/TLR2 signaling pathway. Mol Immunol,2021, 134(7):118-128.
[16] Zhutian Z, Lu L,Yongyan W,et al. Interferon-γ facilitates hepatic antiviral T cell retention for the maintenance of liver-induced systemic tolerance.J Exp Med, 2016, 213(6):1079-1093.
[17] 董静,刘龙梅,陈照林,等. 富马酸替诺福韦二吡呋酯联合双重血浆分子吸附系统序贯血浆置换治疗慢加急性乙型肝炎肝衰竭患者疗效分析. 实用肝脏病杂志,2020,23(5):687-690.
[18] Zhong S, Wang N, Zhao J,et al. Plasma exchange combined with double plasma absorption therapy improve the prognosis of acute-on-chronic liver failure.Chin J Hepatol, 2018, 26(10):744-749.